Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728823 | 0.83 | — | — | |
| SCHEMBL27865425 | 0.81 | CYP11B1 (0.47) | TAAR1CYP11B1CYP11B2DPP4HTR2A | |
| Hydrochloric Acid SCHEMBL3289663 | 0.81 | CYP11B1 (0.47) | TAAR1CYP11B1CYP11B2HRH1DPP4 | |
| SCHEMBL13430054 | 0.79 | CYP11B1 (0.46) | TAAR1CYP11B1CYP11B2TRIM24TRIM33 | |
| SCHEMBL7941717 | 0.79 | CYP11B1 (0.46) | CYP11B1CYP11B2TRIM24TRIM33PARP1 | |
| SCHEMBL3913471 | 0.79 | CYP11B1 (0.46) | CYP11B1CYP11B2TRIM24TRIM33PARP1 | |
| SCHEMBL317658 | 0.77 | BACE1 (0.53) | TAAR1HRH1DPP4HTR2ACHRNA7 | |
| SCHEMBL28126688 | 0.77 | HRH1 (0.47) | TAAR1HRH1DPP4HTR2ACHRNA7 | |
| SCHEMBL30950077 | 0.76 | CYP11B1 (0.44) | CYP11B1CYP11B2TRIM24TRIM33PARP1 | |
| SCHEMBL27938298 | 0.76 | CYP11B1 (0.44) | CYP11B1CYP11B2TRIM24TRIM33PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| US-7078567-B2 | Amination process | JOHNSTON JEFFREY N | 2006-07-18 | — | — | US | disclosed |
| US-20040082778-A1 | Amination process | JOHNSTON JEFFREY N (US) | 2004-04-29 | — | — | US | disclosed |
| US-6670479-B2 | An sp2 hybridized radical is reacted with an azomethine group to form pyrrolidine and indole compounds | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2003-12-30 | — | — | US | disclosed |
| WO-2002072547-A1 | AMINATION PROCESS | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020128490-A1 | Amination process | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002070439-A2 | AMINATION PROCESS | JOHNSTON, JEFFREY, N. | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082778-A1 | Amination process | IDO2, INMT, IDO1 | TAAR1 984/4885CYP11B1 252/4885CYP11B2 26/4885 |
| US-20020128490-A1 | Amination process | IDO2, INMT, IDO1 | TAAR1 760/4885CYP11B1 117/4885CYP11B2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.